Total Payments
$15,855
2024 Payments
$1,466
Companies
38
Transactions
673
Medicare Patients
24,665
Medicare Billing
$2.1M
Payment Breakdown by Category
Food & Beverage$13,816 (87.1%)
Travel$1,566 (9.9%)
Education$348.17 (2.2%)
Other$125.00 (0.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $13,816 | 652 | 87.1% |
| Travel and Lodging | $1,566 | 4 | 9.9% |
| Education | $348.17 | 16 | 2.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $125.00 | 1 | 0.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Boston Scientific Corporation | $2,395 | 31 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $1,652 | 60 | $0 (2024) |
| Amgen Inc. | $1,232 | 62 | $0 (2024) |
| Abbott Laboratories | $935.19 | 26 | $0 (2024) |
| Merck Sharp & Dohme LLC | $859.55 | 36 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $857.16 | 51 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $824.82 | 50 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $721.70 | 43 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $698.11 | 34 | $0 (2023) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $649.42 | 41 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,466 | 77 | Alnylam Pharmaceuticals Inc. ($198.54) |
| 2023 | $2,231 | 97 | Alnylam Pharmaceuticals Inc. ($304.96) |
| 2022 | $2,297 | 117 | Merck Sharp & Dohme LLC ($280.99) |
| 2021 | $1,547 | 96 | Janssen Pharmaceuticals, Inc ($225.82) |
| 2020 | $1,495 | 81 | Astellas Pharma US Inc ($249.19) |
| 2019 | $1,896 | 65 | Abbott Laboratories ($405.61) |
| 2018 | $3,080 | 51 | Boston Scientific Corporation ($1,970) |
| 2017 | $1,842 | 89 | Janssen Pharmaceuticals, Inc ($309.17) |
All Payment Transactions
673 individual payment records from CMS Open Payments — Page 1 of 27
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/22/2024 | Philips North America LLC | (CK7) Extended Holter (Device) | Food and Beverage | Cash or cash equivalent | $7.55 | General |
| Category: Medical Device | ||||||
| 12/22/2024 | Philips North America LLC | (CK7) Extended Holter (Device) | Food and Beverage | Cash or cash equivalent | $4.83 | General |
| Category: Medical Device | ||||||
| 12/17/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $15.82 | General |
| Category: Cardiology | ||||||
| 12/16/2024 | Abbott Laboratories | AVEIR (Device) | Food and Beverage | In-kind items and services | $72.53 | General |
| Category: Cardiac Rhythm Management | ||||||
| 12/12/2024 | Boston Scientific Corporation | WATCHMAN FLX (Device) | Food and Beverage | In-kind items and services | $21.34 | General |
| Category: WATCHMAN FLX_IC | ||||||
| 12/10/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $21.29 | General |
| Category: Cardiovascular | ||||||
| 12/10/2024 | Alnylam Pharmaceuticals Inc. | ONPATTRO (Drug) | Food and Beverage | In-kind items and services | $13.69 | General |
| Category: Genetic Disease | ||||||
| 12/10/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $9.12 | General |
| 12/09/2024 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $15.73 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 12/05/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $18.74 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/04/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $11.97 | General |
| Category: Cardiovascular | ||||||
| 12/02/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $23.40 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 11/26/2024 | Philips North America LLC | (CK7) Extended Holter (Device) | Food and Beverage | Cash or cash equivalent | $17.15 | General |
| Category: Medical Device | ||||||
| 11/12/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $20.53 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 10/30/2024 | Philips North America LLC | (CK7) Extended Holter (Device) | Food and Beverage | Cash or cash equivalent | $10.93 | General |
| Category: Medical Device | ||||||
| 10/30/2024 | Philips North America LLC | (CK7) Extended Holter (Device) | Food and Beverage | Cash or cash equivalent | $6.44 | General |
| Category: Medical Device | ||||||
| 10/24/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $15.39 | General |
| Category: Cardiovascular | ||||||
| 10/23/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $22.99 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/22/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $17.17 | General |
| Category: Cardiology | ||||||
| 10/17/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $22.09 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/15/2024 | Alnylam Pharmaceuticals Inc. | ONPATTRO (Drug) | Food and Beverage | In-kind items and services | $13.37 | General |
| Category: Genetic Disease | ||||||
| 10/07/2024 | Boston Scientific Corporation | WATCHMAN FLX (Device) | Food and Beverage | In-kind items and services | $23.81 | General |
| Category: WATCHMAN FLX_IC | ||||||
| 10/03/2024 | CVRx, Inc. | Barostim Neo System (Device) | Food and Beverage | Cash or cash equivalent | $4.47 | General |
| Category: Heart Failure and Hypertension | ||||||
| 09/18/2024 | Alnylam Pharmaceuticals Inc. | AMVUTTRA (Drug) | Food and Beverage | In-kind items and services | $23.54 | General |
| Category: Genetic Disease | ||||||
| 09/17/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $10.00 | General |
| Category: Cardiovascular | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 32 | 5,794 | 9,114 | $1.1M | $485,386 |
| 2022 | 33 | 6,157 | 9,939 | $1.2M | $578,365 |
| 2021 | 36 | 6,171 | 10,182 | $893,817 | $515,810 |
| 2020 | 35 | 6,543 | 10,494 | $927,376 | $501,431 |
Total Patients
24,665
Total Services
39,729
Medicare Billing
$2.1M
Procedure Codes
149
All Medicare Procedures & Services
149 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 1,285 | 2,235 | $428,975 | $202,987 | 47.3% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 461 | 470 | $133,376 | $67,098 | 50.3% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2023 | 343 | 343 | $94,325 | $47,563 | 50.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 277 | 277 | $99,720 | $33,848 | 33.9% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 1,393 | 1,988 | $49,700 | $20,629 | 41.5% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 180 | 200 | $32,449 | $19,511 | 60.1% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 298 | 313 | $27,139 | $15,714 | 57.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 195 | 207 | $28,224 | $13,522 | 47.9% |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | Office | 2023 | 90 | 498 | $37,350 | $12,790 | 34.2% |
| 93298 | Evaluation of cardiac rhythm monitor system, remote up to 30 days | Office | 2023 | 82 | 478 | $13,414 | $8,896 | 66.3% |
| 93294 | Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | Office | 2023 | 131 | 282 | $9,469 | $5,915 | 62.5% |
| 93296 | Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | Office | 2023 | 158 | 336 | $9,858 | $5,224 | 53.0% |
| 93280 | Programming of dual lead pacemaker system | Office | 2023 | 112 | 154 | $11,823 | $3,813 | 32.2% |
| 93288 | Evaluation of single, dual, multiple lead or leadless pacemaker system | Office | 2023 | 130 | 189 | $9,270 | $2,636 | 28.4% |
| 93248 | Heart rhythm review and interpretation of continous external ekg over 8-15 days | Office | 2023 | 125 | 126 | $8,528 | $2,536 | 29.7% |
| Q9957 | Injection, perflutren lipid microspheres, per ml | Office | 2023 | 32 | 64 | $11,626 | $2,291 | 19.7% |
| 93925 | Ultrasound of leg arteries or artery grafts | Office | 2023 | 17 | 17 | $3,102 | $2,183 | 70.4% |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 2023 | 41 | 45 | $2,855 | $1,814 | 63.6% |
| 93793 | Anticoagulant management of patient taking warfarin | Office | 2023 | 42 | 179 | $5,089 | $1,597 | 31.4% |
| 93970 | Ultrasound study of arm or leg veins with compression and maneuvers | Office | 2023 | 17 | 17 | $3,102 | $1,489 | 48.0% |
| 93295 | Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | Office | 2023 | 28 | 57 | $3,875 | $1,460 | 37.7% |
| 93284 | Programming of multiple lead implantable defibrillator system | Office | 2023 | 22 | 31 | $3,660 | $1,370 | 37.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 18 | 18 | $3,623 | $1,307 | 36.1% |
| G0179 | Physician or allowed practitioner re-certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians a | Office | 2023 | 27 | 39 | $1,838 | $1,151 | 62.6% |
| G0250 | Physician review, interpretation, and patient management of home inr testing for patient with either mechanical heart valve(s), chronic atrial fibrillation, or venous thromboembolism who meets medicare coverage criteria; testing not occurring more frequent | Office | 2023 | 26 | 164 | $4,100 | $1,135 | 27.7% |
About Dr. Daniel Parnassa, MD
Dr. Daniel Parnassa, MD is a Cardiovascular Disease healthcare provider based in Sebring, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/08/2005. The National Provider Identifier (NPI) number assigned to this provider is 1528049483.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Daniel Parnassa, MD has received a total of $15,855 in payments from pharmaceutical and medical device companies, with $1,466 received in 2024. These payments were reported across 673 transactions from 38 companies. The most common payment nature is "Food and Beverage" ($13,816).
As a Medicare-enrolled provider, Parnassa has provided services to 24,665 Medicare beneficiaries, totaling 39,729 services with total Medicare billing of $2.1M. Data is available for 4 years (2020–2023), covering 149 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Sebring, FL
- Active Since 11/08/2005
- Last Updated 12/28/2021
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1528049483
Products in Payments
- WATCHMAN (Device) $2,054
- XARELTO (Drug) $1,532
- Repatha (Biological) $1,060
- ELIQUIS (Drug) $978.70
- VERQUVO (Drug) $721.44
- FARXIGA (Drug) $604.57
- MULTAQ (Drug) $568.91
- ONPATTRO (Drug) $496.69
- JARDIANCE (Drug) $477.22
- Mitra Clip system (Device) $370.01
- ENTRESTO (Drug) $361.38
- LEQVIO (Drug) $360.32
- Vascepa (Drug) $329.92
- PRALUENT (Drug) $254.20
- Kerendia (Drug) $252.24
- PRADAXA (Drug) $250.74
- NEXLETOL (Drug) $234.23
- CAMZYOS (Drug) $216.28
- PRALUENT ALIROCUMAB INJECTION (Biological) $202.35
- LifeVest (Device) $200.30
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Sebring
Dr. Rakesh Sharma, M.d, M.D
Cardiovascular Disease — Payments: $10,129
Cardiovascular Disease $10,129
Ms. Joan Siracuse, Md, MD
Cardiovascular Disease — Payments: $7,744
Cardiovascular Disease $7,744
Ramon Torres, Md, MD
Cardiovascular Disease — Payments: $6,611
Cardiovascular Disease $6,611
Dr. George Leef, Md, MD
Cardiovascular Disease — Payments: $5,594
Cardiovascular Disease $5,594
Harini Lakshman, Md, MD
Cardiovascular Disease — Payments: $4,683
Cardiovascular Disease $4,683
Dr. Laura Mosher, Md, MD
Cardiovascular Disease — Payments: $4,579
Cardiovascular Disease $4,579